A novel prognostic model utilizing pathological signatures effectively predicts postoperative recurrence risk and sorafenib response in hepatocellular carcinoma (HCC) patients. Analyzed across 287 non-treated patients, the model achieved AUROC values of 0.818 and 0.811 for predicting one and two-year recurrence respectively. Validation with an external cohort confirmed its predictive power. Additionally, it successfully stratified sorafenib-treated patients, highlighting significant survival differences, thereby supporting clinical decision-making and enhancing patient stratification.
Journal Article by Li Y, Xiong J (…) Liu L et 5 al. in BMC Med
© 2025. The Author(s).